D. Osoba

发表

Measuring health-related quality of life.

D. Osoba, I. Tannock, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life and oral function following radiotherapy for head and neck cancer

D. Osoba, N. Le, J. Epstein, 1999, Head & neck.

Current applications of health-related quality-of-life assessment in oncology

D. Osoba, 1997, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

Stated Preferences of Patients with Cancer for Health-related Quality-of-life (HRQOL) Domains During Treatment

D. Osoba, F. Johnson, C. Copley-Merriman, 2006, Quality of Life Research.

Are Chemotherapy Patients’ HRQoL Importance Weights Consistent with Linear Scoring Rules? A Stated-choice Approach

John Coombs, A. Brett Hauber, F. Reed Johnson, 2006, Quality of Life Research.

Evidence for a Humoral Thymus Factor Responsible for the Maturation of Immunological Faculty

D. Osoba, J. Miller, J. Miller, 1963, Nature.

THE EFFECTS OF THYMUS AND OTHER LYMPHOID ORGANS ENCLOSED IN MILLIPORE DIFFUSION CHAMBERS ON NEONATALLY THYMECTOMIZED MICE

D. Osoba, 1965, The Journal of experimental medicine.

Lessons learned from measuring health-related quality of life in oncology.: 1

D. Osoba, 1994 .

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

D. Osoba, F. Shepherd, A. Willan, 1987, Annals of internal medicine.

Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.

G. Guyatt, D. Osoba, K. Torfs, 1998, European journal of cancer.

D. Osoba, R. Mirimanoff, R. Stupp, 2005, The Lancet. Oncology.

The EORTC Core Quality-of-Life Questionnaire: Interim Results of an International Field Study *

D. Osoba, S. Schraub, S. Kaasa, 2021, Effect of Cancer on Quality of Life.

Assessing quality of life in clinical trials.

D. Osoba, J. Pater, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Recommendations for the use of antiemetics

D. Osoba, S. Groshen, J. Silber, 1999 .

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.

D. Osoba, N. Murray, K. Goddard, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line therapy with VP-16 and cisplatin for small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1986, Seminars in oncology.

THE ASSOCIATION OF THE HUMAN HISTOCOMPATIBILITY SYSTEM WITH HODGKIN'S DISEASE

D. Osoba, J. Falk, 1974 .

HL-A antigens and survival in Hodgkin's disease.

D. Osoba, J. Falk, 1971, Lancet.

Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.

D. Osoba, J. Connors, J. Goldie, 1992, Seminars in oncology.

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.

D. Osoba, R. Livingston, D. Gandara, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kaposi's sarcoma in recipients of renal transplants.

D. Osoba, C. Cardella, A. Harwood, 1979, The American journal of medicine.

Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

D. Osoba, M. Piccart, E. Eisenhauer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

D. Osoba, S. Groshen, J. Silber, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of drug therapy problems among outpatient hypertensive and type-2-diabetic patients at a Tertiary Hospital, South-West Nigeria

D. Osoba, R. Adisa, 2020, Nigerian Journal of Pharmaceutical Research.

D. Osoba, 2007, Supportive Care in Cancer.

The use of oral BCG in the treatment or metastatic malignant melanoma.

D. Osoba, K. Pritchard, M. A. Baker, 1976, Medical and pediatric oncology.

Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30

D. Osoba, J. Pater, M. Palmer, 1997, Supportive Care in Cancer.

D. Osoba, J. Dancey, J. Myles, 1996, Journal of the National Cancer Institute. Monographs.

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

D. Osoba, D. Slamon, M. Murphy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thymic function, immunologic deficiency, and autoimmunity.

D. Osoba, 1972, The Medical clinics of North America.

Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.

D. Osoba, M. Blackstein, K. Pritchard, 1981, Cancer treatment reports.

Quality-of-life assessment: patient compliance with questionnaire completion.

D. Osoba, M. Levine, J. Pater, 1992, Journal of the National Cancer Institute.

Effects of Altering the Time of Administration and the Time Frame of Quality of life Assessments in Clinical Trials: An Example Using the EORTC QLQ-C30 in a Large Anti-Emetic Trial

D. Osoba, J. Pater, B. Zee, 1998, Quality of Life Research.

Patient-Reported Outcomes and Health-Related Quality of Life

D. Osoba, 2007 .

Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy.

D. Osoba, K. Gelmon, M. Knowling, 1994, Oncology.

D. Osoba, M. Prados, W. Yung, 2000, European journal of cancer.

D. Osoba, M. Prados, M. Brada, 2000 .

Methods to explain the clinical significance of health status measures.

Gordon H Guyatt, Albert W Wu, Geoffrey R Norman, 2002, Mayo Clinic proceedings.

Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis.

D. Osoba, A. Fam, F. Leung, 1981, The American journal of medicine.

Interpreting the meaningfulness of changes in health‐related quality of life scores: Lessons from studies in adults

D. Osoba, 1999, International journal of cancer. Supplement = Journal international du cancer. Supplement.

D. Osoba, D. Slamon, M. Murphy, 2001 .

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial

D. Osoba, J. Menten, W. Mason, 2021, Neuro-oncology advances.

Efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck cancer.

D. Osoba, J. Connors, J. Goldie, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy

D. Osoba, L. Yelle, J. Rusthoven, 1998, Supportive Care in Cancer.

Quality of life studies in chemotherapy-induced emesis.

D. Osoba, B. Zee, J. Pater, 1996, Oncology.

Mixed leukocyte reaction in rheumatoid arthritis.

D. Osoba, M. Urowitz, E. Keystone, 1976, Arthritis and rheumatism.

Stated preferences of patients with cancer for health-related quality-of-life domains during treatment

D. Osoba, Reed Johnson, C. Copley-Merriman, 2003 .

Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen.

D. Osoba, C. Little, N. Murray, 1991, Journal of the National Cancer Institute.

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

D. Osoba, J. Rusthoven, F. Shepherd, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.

D. Osoba, D. Payne, J. Pater, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current concepts of the immunological function of the thymus.

D. Osoba, J. Miller, J. Miller, 1967, Physiological reviews.

A HUMORAL THYMUS MECHANISM RESPONSIBLE FOR IMMUNOLOGIC MATURATION *

D. Osoba, P. Dukor, J.F.A.P. Miller, 1965, Annals of the New York Academy of Sciences.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

D. Osoba, I. Tannock, M. Stockler, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Osoba, David Osoba, 2000, Supportive Care in Cancer.

Characterization of culture-induced cytotoxicity from human peripheral lymphocyte subpopulations.

D. Osoba, J. Rusthoven, 1986, Cellular immunology.

HLA-B8 phenotype associated with an increased mixed leukocyte reaction

D. Osoba, J. Falk, 1978, Immunogenetics.

The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial.

D. Osoba, D. Payne, J. Pater, 1988, International journal of radiation oncology, biology, physics.

"Spontaneous" progressive multifocal leukoencephalopathy. Immunologic aspects.

D. Osoba, A. Knight, P. O'Brien, 1972, Annals of internal medicine.

The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.

D. Osoba, A. Willan, M. Levitt, 1986, Seminars in oncology.

Quality of life assessment: Patient compliance with questionnaire completion

D. Osoba, M. Levine, J. Pater, 1991 .

Interpreting the significance of changes in health-related quality-of-life scores.

D. Osoba, B. Zee, J. Myles, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Treatment on Health-Related Quality of Life in Acquired Immunodeficiency Syndrome (AIDS)-Related Kaposi's Sarcoma: A Randomized Trial of Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine

D. Osoba, D. Northfelt, D. Budd, 2001, Cancer investigation.

Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.

D. Osoba, A. Willan, C. Erlichman, 1986, Clinical and investigative medicine. Medecine clinique et experimentale.

ArticlesQuality of Life

D. Osoba, 1986 .

VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

D. Osoba, G. Deboer, R. Feld, 1984, Cancer.

Chapter 17 – NON-SMALL-CELL LUNG CANCER: BLEOMYCIN PLUS ETOPOSIDE AND CISPLATIN

D. Osoba, F. Shepherd, M. Blackstein, 1985 .

Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma

D. Osoba, N. Aaronson, M. Muller, 1997, Journal of Neuro-Oncology.

Nude mice--a model system for studying the cellular basis of the humoral immune response.

D. Osoba, B. Croy, 1973, Cellular immunology.

DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.

D. Osoba, K. Pritchard, I. Quirt, 1980, Cancer treatment reports.

Effect of Cancer On Quality of Life

D. Osoba, 1991 .

DIFFERENTIATION OF THYMUS-DERIVED CELLS FROM PRECURSORS IN MOUSE BONE MARROW

D. Osoba, M. El-Arini, 1973, The Journal of experimental medicine.

THE LYMPHOID TISSUES AND IMMUNE RESPONSES OF NEONATALLY THYMECTOMIZED MICE BEARING THYMUS TISSUE IN MILLIPORE DIFFUSION CHAMBERS

D. Osoba, J. Miller, J. Miller, 1964, The Journal of experimental medicine.

Use of genetically defined nude mice in the study of the mixed leukocyte reaction.

D. Osoba, B. Croy, 1974, Journal of immunology.

IMMUNE REACTIVITY IN MICE THYMECTOMIZED SOON AFTER BIRTH: NORMAL RESPONSE AFTER PREGNANCY.

D. Osoba, 1965, Science.

Growth of a human carcinoma of the cervix in mice thymectomized at birth.

D. Osoba, N. Auersperg, 1966, Journal of the National Cancer Institute.

Immune Reactivity in Mice Thymectomized Soon after Birth: Normal Response after Pregnancy

D. Osoba, 1965, Science.

A Quantitative Assay for the Mixed Leukocyte Reaction by Mouse Spleen Cells

D. Osoba, M. El-Arini, 1973 .

Use of liposomal anthracyclines in Kaposi's sarcoma.

D. Osoba, D. Northfelt, S. Krown, 2004, Seminars in oncology.

Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

D. Osoba, J. Menten, W. Mason, 2017, The New England journal of medicine.

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Murielle Mauer, Corneel Coens, Andrew Bottomley, 2009, The Lancet. Oncology.

Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Corneel Coens, Andrew Bottomley, John Maringwa, 2011, Journal of the National Cancer Institute.

Guidelines for reporting results of quality of life assessments in clinical trials

D. Osoba, D. Machin, M. Staquet, 1996, Quality of Life Research.

D. Osoba, M. Prados, W. Yung, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A simple freezing and storage method to preserve the stimulating function of leukocytes in the mixed leukocyte reaction.

D. Osoba, J. Falk, M. Dajko, 1975, Tissue antigens.

Role of theHLA complex in the antibody response to malaria under natural conditions

D. Osoba, T. Goosen, H. Dick, 1979, Immunogenetics.

The mixed-leukocyte reaction in man: effect of pools of stimulating cells selected on the basis of crossreacting HL-A specificities.

D. Osoba, J. Falk, 1974, Cellular Immunology.

Febrile morbidity in relation to cone biopsy followed by hysterectomy: a study of 38 patients.

D. Osoba, 1958, Canadian Medical Association journal.

Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer

D. Osoba, J. Pater, B. Zee, 1994, Quality of Life Research.

Lessons learned from measuring health-related quality of life in oncology.

D. Osoba, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy

D. Osoba, J. Dancey, J. Pater, 2004, Quality of Life Research.

Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

D. Osoba, A. Coates, F. Porzsolt, 1997, European journal of cancer.

Predictive value of staging investigations in patients with clinical stage I malignant melanoma.

D. Osoba, L. From, G. Deboer, 1987, Plastic and reconstructive surgery.

The value of staging and serial follow‐up investigations in patients with completely resected, primary, cutaneous malignant melanoma

D. Osoba, L. From, G. Deboer, 1985, The British journal of surgery.

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

D. Osoba, J. Olson, M. Prados, 2000, British Journal of Cancer.

D. Osoba, I. Tannock, A. Neville, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

D. Osoba, M. Taphoorn, C. Gotay, 2014, Cancer.

D. Osoba, 2011, Therapeutic advances in medical oncology.

Missing quality of life data in cancer clinical trials: serious problems and challenges.

D. Osoba, L. Fallowfield, D. Cella, 1998, Statistics in medicine.

Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.

D. Osoba, A. Bezjak, M. Brundage, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.

D. Osoba, J. Pater, J. Latreille, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting survival using health related quality of life scores in glioblastoma cancers: Findings from an international phase III randomised controlled trial

D. Osoba, R. Stupp, W. Mason, 2005 .

Physical properties of mouse spleen cells involved in the mixed leukocyte reaction and graft-vs-host disease.

D. Osoba, M. El-Arini, 1973, Journal of immunology.

Effect of postchemotherapy nausea and vomiting on health-related quality of life

D. Osoba, J. Pater, B. Zee, 1997, Supportive Care in Cancer.

Letters to the editor: Assessing quality of life in clinical trials

D. Osoba, J. Pater, 1993 .

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

D. Johnston, D. Osoba, F. Shepherd, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.

D. Osoba, K. Gelmon, M. Knowling, 1994, Oncology.

A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).

D. Osoba, J. Menten, W. Mason, 2016 .

Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data

D. Osoba, M. Taphoorn, C. Gotay, 2011, Expert review of pharmacoeconomics & outcomes research.

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

D. Osoba, N. Aaronson, M. Muller, 1996, Quality of Life Research.

Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G.

D. Osoba, M. Stockler, D. Cella, 2010, Journal of clinical epidemiology.

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of disease burden on health-related quality of life in patients with malignant gliomas.

D. Osoba, M. Prados, W. Yung, 2000, Neuro-oncology.

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.

D. Osoba, R. Stupp, M. J. van den Bent, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

D. Osoba, M. Stockler, D. Cella, 2022 .

Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.

D. Osoba, A. Willan, C. Erlichman, 1991, Journal of the National Cancer Institute.

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

D. Osoba, R. Mirimanoff, R. Stupp, 2007, British Journal of Cancer.

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients.

D. Osoba, R. Mirimanoff, R. Stupp, 2010, European journal of cancer.

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

D. Osoba, I. Tannock, K. Murphy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

D. Osoba, M. Tonato, R. Gralla, 2005, Supportive Care in Cancer.

Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting

D. Osoba, J. Pater, B. Zee, 1994, Supportive Care in Cancer.

A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.

D. Osoba, J. Pater, J. Latreille, 1992, European journal of cancer.

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

D. Osoba, B. Zee, J. Pater, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.

D. Osoba, M. Fitch, D. Warr, 1995, The Canadian journal of oncology.

Measuring the Effect of Cancer on Health-Related Quality of Life

D. Osoba, 1995, PharmacoEconomics.

Measuring chemotherapy‐induced nausea and emesis

Charles G. Martin, D. Osoba, L. Elting, 2003, Cancer.

Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer

D. Osoba, B. Zee, N. Aaronson, 1997, Quality of Life Research.

RESTRICTION OF THE CAPACITY TO RESPOND TO TWO ANTIGENS BY SINGLE PRECURSORS OF ANTIBODY-PRODUCING CELLS IN CULTURE

D. Osoba, 1969, The Journal of experimental medicine.

Authors and Disclosures

D. Osoba, 2011 .

From Therapeutic Advances in Medical Oncology Health-related Quality of Life and Cancer Clinical Trials

D. Osoba, 2011 .

Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?

D. Osoba, C. Gotay, A. Bottomley, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of significant others as proxy raters of the quality of life of patients with brain cancer.

D. Osoba, N. Aaronson, M. Muller, 1997, Medical care.

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

D. Osoba, P. Goss, B. Norris, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations on health-related quality of life research to support labeling and promotional claims in the United States

I. Barofsky, D. Osoba, N. Leidy, 2004, Quality of Life Research.

The clinical value and meaning of health-related quality-of-life outcomes in oncology

D. Osoba, C. Gotay, C. Snyder, 2004 .

The Karnofsky performance status scale re-examined: a cross-validation with the EORTC-C30

D. Osoba, J. Schaafsma, 1994, Quality of Life Research.

A Taxonomy of the Uses of Health-Related Quality-of-Life Instruments in Cancer Care and the Clinical Meaningfulness of the Results

D. Osoba, 2002, Medical care.

D. Osoba, 2000 .

Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology.

D. Osoba, 1993, Cancer treatment reviews.

The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer

D. Osoba, A. Bezjak, P. Warde, 2004, Quality of Life Research.

Methods for explaining the clinical significance of health status measures

G. Guyatt, D. Osoba, A. Wu, 2002 .

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

D. Osoba, M. Taphoorn, C. Gotay, 2011, Supportive Care in Cancer.

Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience.

D. Osoba, A. Bezjak, M. Brundage, 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Translating the science of patient-reported outcomes assessment into clinical practice.

D. Osoba, David Osoba, 2007, Journal of the National Cancer Institute. Monographs.

What has been learned from measuring health-related quality of life in clinical oncology.

D. Osoba, 1999, European journal of cancer.

Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.

D. Osoba, A. Bezjak, M. Brundage, 2005, European journal of cancer.

Patients' experiences using a computerized program with a touch-sensitive video monitor for the assessment of health-related quality of life.

D. Osoba, J. Buxton, D. Osoba, 1998, Quality of Life Research.

Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative.

D. Osoba, M. Taphoorn, C. Gotay, 2009, European journal of cancer care.

Effect of rifamycin-SV derivatives on immunologic responses in culture.

D. Osoba, 1974, Journal of immunology.

Combined chemotherapy and radiation therapy for non-small-cell lung cancer.

D. Osoba, J. Rusthoven, W. Evans, 1986, Seminars in oncology.

The functions of the thymus.

D. Osoba, 1966, Canadian Medical Association journal.

The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions

D. Osoba, 1992, Quality of Life Research.

Research on health-related quality of life: dissemination into practical applications

D. Osoba, J. Till, J. Pater, 1994, Quality of Life Research.

Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making.

D. Osoba, C. Gotay, A. Bottomley, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life III: translating the science of quality-of-life assessment into clinical practice-an example-driven approach for practicing clinicians and clinical researchers.

David Cella, Gordon Guyatt, Jeff A Sloan, 2003, Clinical therapeutics.

SOME PHYSICAL AND RADIOBIOLOGICAL PROPERTIES OF IMMUNOLOGICALLY REACTIVE MOUSE SPLEEN CELLS

D. Osoba, 1970, The Journal of experimental medicine.

Preliminary characterization of the cell in nu/nu mice that responds in the mixed leukocyte reaction.

D. Osoba, B. Croy, 1975, Clinical immunology and immunopathology.

Effect of Pregnancy on the Restoration of Immunological Responses in Neonatally Thymectomized Female Mice

D. Osoba, 1973 .

Responsiveness in the mixed leukocyte reaction by nu/nu mouse cells bearing Thy-1 antigen and lacking Fc receptors.

D. Osoba, M. Letarte, M. M. Feneck, 1981, Cellular immunology.

D. Osoba, M. Prados, W. Yung, 2000 .

Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy.

D. Osoba, D Osoba, 1996, Cancer treatment reviews.

D. Osoba, J. Till, J. Pater, 1995, The Canadian journal of oncology.

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.

D. Osoba, B. Zee, 1998, Statistics in medicine.

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

D. Osoba, S. Schraub, S. Kaasa, 1993, Journal of the National Cancer Institute.

Canadian cancer care: organizational models.

D. Osoba, J. Rusthoven, H. Wodinsky, 1986, Annals of internal medicine.

D. Osoba, M. Burchmore, 1999, Seminars in oncology.

The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG

D. Osoba, R. Mirimanoff, R. Stupp, 2008 .

Emesis induced by low or minimal emetic risk chemotherapy

D. Osoba, M. Tonato, E. Ballatori, 2005, Supportive Care in Cancer.

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

A. Favero, D. Osoba, M. Kris, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The prognostic value of HLA phenotypes in Hodgkin's disease

D. Osoba, A. Ciampi, J. Till, 1980, Cancer.

Guidelines for measuring health-related quality of life in clinical trials

D. Osoba, 1998 .

D. Osoba, M. Stockler, D. Cella, 2022 .

Requirement of a Nonproliferating Class of Cells for Generation of Immune Responses in Cell Culture 1

D. Osoba, James H. Goldie, 1970, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Current concepts of the immunological function of the thymus.

D. Osoba, J. Miller, 1967, Physiological reviews.

D. Osoba, N. Aaronson, M. Muller, 1997 .

Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune

D. Osoba, J. Langston, J. Hirsh, 1987 .